Ftse Mib
34.230,30
-0,42%
DAX
18.486,45
-0,61%
S&P 500
5.631,22
0,28%
NASDAQ
0,00
0,00%
Bitcoin
63.794,16
-1,63%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Applied Therapeutics Inc (APLT) Applied Therapeutics Inc (APLT) Notizie

APLT

Applied Therapeutics (APLT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLT
DataOraFonteTitoloSimboloCompagnia
04/01/202422:05GlobeNewswire Inc.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyNASDAQ:APLTApplied Therapeutics Inc
03/01/202417:20Dow Jones NewsApplied Therapeutics Shares Hit 52-Week High on Govorestat FilingsNASDAQ:APLTApplied Therapeutics Inc
03/01/202415:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLTApplied Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
23/12/202302:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLTApplied Therapeutics Inc
13/11/202323:10Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:APLTApplied Therapeutics Inc
09/11/202313:47Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLTApplied Therapeutics Inc
09/11/202313:30GlobeNewswire Inc.Applied Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
03/11/202321:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLTApplied Therapeutics Inc
02/11/202312:00GlobeNewswire Inc.Applied Therapeutics to Present at the UBS Biopharma Conference 2023NASDAQ:APLTApplied Therapeutics Inc
01/11/202312:00GlobeNewswire Inc.Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7NASDAQ:APLTApplied Therapeutics Inc
28/09/202313:00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingNASDAQ:APLTApplied Therapeutics Inc
06/09/202317:08Dow Jones NewsApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDANASDAQ:APLTApplied Therapeutics Inc
06/09/202313:00GlobeNewswire Inc.Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023NASDAQ:APLTApplied Therapeutics Inc
11/08/202322:47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLTApplied Therapeutics Inc
10/08/202313:00GlobeNewswire Inc.Applied Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
25/07/202313:00GlobeNewswire Inc.Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNASDAQ:APLTApplied Therapeutics Inc
23/06/202322:41Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APLTApplied Therapeutics Inc
22/06/202313:00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes AssociationNASDAQ:APLTApplied Therapeutics Inc
16/06/202322:41Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:APLTApplied Therapeutics Inc
15/06/202313:00GlobeNewswire Inc.Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve SocietyNASDAQ:APLTApplied Therapeutics Inc
25/05/202313:00GlobeNewswire Inc.Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD DeficiencyNASDAQ:APLTApplied Therapeutics Inc
22/05/202312:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:APLTApplied Therapeutics Inc
19/05/202322:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:APLTApplied Therapeutics Inc
11/05/202313:00GlobeNewswire Inc.Applied Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
10/05/202318:03Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:APLTApplied Therapeutics Inc
05/05/202322:55Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:APLTApplied Therapeutics Inc
28/04/202322:46Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:APLTApplied Therapeutics Inc
24/04/202313:00GlobeNewswire Inc.Applied Therapeutics, Inc. Announces $30 Million Private Placement of EquityNASDAQ:APLTApplied Therapeutics Inc
24/04/202313:00GlobeNewswire Inc.Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA SubmissionNASDAQ:APLTApplied Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APLT

La tua Cronologia

LSE
ALTN
Altyngold
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network